Search
Ertugliflozin
go.drugbank.com/drugs/DB11827ApprovedInvestigational[A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.
Categories: Drugs Used in DiabetesSynonyms: 1,6-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-β-L-idopyranose, β-L-Idopyranose, 1,6-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-5-C-(hydroxymethyl)-Streptococcus pneumoniae type 5 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10323ApprovedInvestigationalStreptococcus pneumoniae type 5 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 5 of *Streptococcus pneumoniae*. … It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheStreptococcus pneumoniae type 23f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10340ApprovedInvestigationalStreptococcus pneumoniae type 23f capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 23f of *Streptococcus pneumoniae … It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: PNEUMOVAX 23 Injektionslösung in einer Fertigspritze, PNEUMOVAX 23 Injektionslösung in einer DurchstechflascheDonidalorsen
go.drugbank.com/drugs/DB18751ApprovedInvestigational[L53788] Donidalorsen was approved by the FDA in August 2025 for prophylactic use to prevent HAE attacks.[L53783,L53788] It is the first RNA-targeted therapy approved for HAE.[L53783] … Hereditary angioedema (HAE) is a rare genetic disease characterized by recurrent episodes of severe swelling induced by excessive production of bradykinin.
Categories: Drugs Used in Hereditary AngioedemaSynonyms: -(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL), DNA, D((2'-O-(2-METHOXYETHYL))M5RU-SP-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RA-SP-G-SP-T-SP-M5C-SP-T-SP-M5C-SP-T-SP-T-SP-G-SP-G-SP-M5C-SPDroxidopa
go.drugbank.com/drugs/DB06262ApprovedInvestigationalEurope. … Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S.
Synonyms: L-DOPS, L-DihydroxyphenylserineTebentafusp
go.drugbank.com/drugs/DB15283ApprovedInvestigational[L39995] It is a bispecific, fusion protein and first-in-class drug of immune-mobilizing monoclonal T cell receptors against cancer (ImmTACs), a recently developed cancer immunotherapy with a novel mechanism … [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675]
Categories: Bispecific gp100 Peptide-HLA-directed CD3 T Cell EngagerVarenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalIn addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. … Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist.
Categories: Drugs Used in Addictive Disorders, Drugs Used in Nicotine DependenceBordetella pertussis toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB14388ApprovedInvestigationalBordetella pertussis toxoid antigen (formaldehyde inactivated) is a vaccine.
Mixtures: -POLIO SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE, Repevax Injektionssuspension in einer FertigspritzeEteplirsen
go.drugbank.com/drugs/DB06014ApprovedInvestigationalIt consists of a six-membered morpholino ring replacing the five-membered ribofuranosyl rings found in natural DNA and RNA. … Eteplirsen was first approved by the FDA in September 2016 for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene, which codes for dystrophin, that
Categories: Compounds used in a research, industrial, or household settingSynonyms: )-1-piperazinyl)-N,N-dimethylphosphonamidate) RNA, (P-deoxy-P-(dimethylamino)](2',3'-dideoxy-2',3'-imino-2',3'-seco)(2'a→5')(C-m5U-C-C-A-A-C-A-m5U-C-A-A-G-G-A-A-G-A-m5U-G-G-C-A-m5U-m5U-m5U-C-m5U-A-G),5'-(P-(4-((2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)carbonylPafolacianine
go.drugbank.com/drugs/DB15413ApprovedInvestigationalPafolacianine, or OTL38, is a folate analogue conjugated with a fluorescent dye that absorbs light in the near-infrared (NIR) spectrum [A242572] within a range of 760 nm to 785 nm, with a peak absorption … It emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.
Categories: Compounds used in a research, industrial, or household setting